A 68-year-old woman with type 2 diabetes mellitus, essential hypertension, and a history o… — USMLE Step 3

A 68-year-old woman with type 2 diabetes mellitus, essential hypertension, and a history of a transient ischemic attack (TIA) 2 years ago visits her primary care physician. She is currently asymptomatic and recovering well. Her most recent hemoglobin A1c is $7.1\%$ on a regimen of metformin and glipizide. Her blood pressure is $128/78 \text{ mmHg}$ on lisinopril. Echocardiography performed last year showed normal left ventricular size and systolic function with an estimated ejection fraction of $60\%$ .

She brings in a pharmaceutical magazine advertisement for a new sodium-glucose cotransporter-2 (SGLT2) inhibitor, "CardioGlitin." The advertisement prominently features the claim: "Proven to reduce the risk of major cardiovascular events by $18\%$ !" The patient is very anxious about having a full stroke and asks if she should switch to this new medication specifically to lower her risk.

The physician reviews the pivotal randomized controlled trial referenced in the advertisement. The trial evaluated the drug against placebo in over 8,000 patients with type 2 diabetes and high cardiovascular risk over 4 years. The results for the primary composite endpoint (major adverse cardiovascular events) and its individual components are presented below:

Outcome	Hazard Ratio ( $95\%$ CI)
Primary Composite Endpoint	$0.82$ ( $0.73 - 0.92$ )
Cardiovascular Death	$0.98$ ( $0.85 - 1.13$ )
Non-fatal Myocardial Infarction	$0.95$ ( $0.81 - 1.11$ )
Non-fatal Stroke	$1.04$ ( $0.87 - 1.24$ )
Hospitalization for Heart Failure	$0.61$ ( $0.50 - 0.74$ )

Based on the provided trial data, which of the following is the most appropriate response to the patient's inquiry?

The advertised overall benefit is primarily driven by a reduction in heart failure admissions, and the trial data does not show a statistically significant reduction in the risk of stroke.Answer
B
The medication is highly recommended for you because the statistically significant $18\%$ reduction in the composite endpoint guarantees a proportional decrease in your specific risk of stroke.
C
We cannot apply these results to your care because your history of a transient ischemic attack acts as a confounder that modifies the treatment effect.
D
The medication should be avoided because agents that drastically reduce heart failure hospitalizations are pharmacologically contraindicated in patients with prior cerebrovascular events.
E
The results regarding stroke risk are statistically invalid because the researchers likely used an inappropriate inferential test to evaluate the individual components of the composite endpoint.

Answer

The most appropriate response is that the advertised benefit is driven by a reduction in heart failure admissions, and there is no statistically significant reduction in the risk of stroke.

The correct answer accurately interprets the provided statistical data. While the advertisement truthfully claims an

18\%

reduction in major cardiovascular events (the primary composite endpoint, HR

0.82

), a closer look at the trial data reveals that this benefit is driven entirely by a reduction in hospitalizations for heart failure (HR

0.61

95\%

0.50 - 0.74

). The patient is specifically asking about stroke prevention. The hazard ratio for non-fatal stroke is

1.04

with a

95\%

confidence interval of

0.87 - 1.24

. Because this interval crosses the null value of

1.0

, the trial failed to demonstrate a statistically significant benefit for stroke prevention. The physician must accurately translate these nuances to the patient rather than taking the composite marketing claim at face value.

Step-by-Step Solution

Identify the patient's specific clinical goal.

The patient wants to know if the medication will lower her risk of having a stroke.

Treatment decisions must align the available evidence with the patient's specific clinical needs and concerns.

Analyze the primary composite endpoint in the provided table.

The primary composite endpoint shows a statistically significant benefit with a Hazard Ratio of

0.82

(an

18\%

relative risk reduction) because the

95\%

confidence interval (

0.73 - 0.92

) does not cross

1.0

This confirms the advertisement's claim is technically accurate based on the overall composite outcome.

Evaluate the individual components comprising the composite endpoint.

The only individual component that is statistically significant is 'Hospitalization for Heart Failure' (HR

0.61

95\%

0.50 - 0.74

). The components for CV Death, MI, and Stroke all have confidence intervals that cross

1.0

Composite endpoints pool different events to increase statistical power, but a large effect size in one component can drive the entire result, masking null effects in others.

Correlate the findings with the patient's goal.

The Hazard Ratio for non-fatal stroke is

1.04

(

95\%

0.87 - 1.24

). Because the confidence interval crosses

1.0

, the drug does not significantly reduce stroke risk.

The physician must educate the patient that the marketing claim, while true for the composite endpoint, does not apply to her specific clinical goal of stroke prevention.

Key Concept

Deconstructing composite endpoints and interpreting confidence intervals for individual components in medical literature.

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic